Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs for osteosarcoma-targeted therapy.

Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs for osteosarcoma-targeted therapy. Eur J Pharm Biopharm. 2020 Jan 17;: Authors: Pereira-Silva M, Alvarez-Lorenzo C, Concheiro A, Cláudia Santos A, Veiga F, Figueiras A Abstract Osteosarcoma(OS) represents the main cancer affecting bone tissue, and one of the most frequent in children. In this review we discuss the major pathological hallmarks of this pathology, its current therapeutics, new active biomolecules, as well as the nanotechnology outbreak applied to the development of innovative strategies for selective OS targeting. Small RNA molecules play a role as key-regulator molecules capable of orchestrate different responses in what concern cancer proliferation, migration and invasiveness. Frequently associated with lung metastasis, new strategies are urgent to upgrade the therapeutic outcomes and the life-expectancy prospects. Hence, the prominent rise of micelleplexes as multifaceted and efficient structures for small nucleic acid delivery and selective drug targeting is revisited here with special emphasis in ligand-mediated active targeting. Future landmarks towards the development of novel nanostrategies for both OS diagnosis and OS therapy improvements are also discussed. PMID: 31958514 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Biopharm Source Type: research